Trial · NCT05049850
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients With DSA Rebound | Imlifidase | 0 | Participants | ||
| Proportion of Patients With Kidney Biopsy Proven AMR | Imlifidase | 1 | Participants | ||
| Proportion of Patient With DSA Rebound | Imlifidase | 0 | Participants | ||
| Proportion of Patients With Negative FCXM | Imlifidase | 3 | Participants | ||
| Levels of DSA | Imlifidase | Patient 1, pre-dose | 22311 | MFI | |
| Levels of DSA | Imlifidase | Patient 1, Day 181 | 8619 | MFI | |
| Levels of DSA | Imlifidase | Patient 2, pre-dose | 8526 | MFI | |
| Levels of DSA | Imlifidase | Patient 2, Day 139 | 2172 | MFI | |
| Levels of DSA | Imlifidase | Patient 3, pre-dose | 9994 | MFI | |
| Levels of DSA | Imlifidase | Patient 3, Day 181 | 149 | MFI | |
| Number of Participants With Graft Survival | Imlifidase | 3 | Participants | ||
| Patients Survival | Imlifidase | 3 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Imlifidase | 3 | Participants | ||
| Kidney Function Assessed by Creatinine | Imlifidase | Pre-dose | 506 | Full Range 305 to 682 | μmol/L |
| Kidney Function Assessed by Creatinine | Imlifidase | Day 181 | 180 | Full Range 91 to 184 | μmol/L |
| Kidney Function Assessed by Estimated Glomerular Filtration Rate (eGFR) | Imlifidase | Pre-dose | 11 | Full Range 6 to 14 | mL/min/1.73m2 |
| Kidney Function Assessed by Estimated Glomerular Filtration Rate (eGFR) | Imlifidase | Day 181 | 35 | Full Range 26 to 60 | mL/min/1.73m2 |
| Kidney Function Assessed by Protein/Creatinine Ratio in Urine | Imlifidase | 24h post-dose | 2158 | Full Range 1900 to 120025 | mg/g |
| Kidney Function Assessed by Protein/Creatinine Ratio in Urine | Imlifidase | Day 181 | 1233 | Full Range 470 to 1996 | mg/g |
| Imlifidase Pharmacokinetics (AUC) | Imlifidase | 71.9 | Full Range 65.6 to 119 | h×μg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05049850/results